Search

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

EHA2023 Gallery

We extend our gratitude to the esteemed Faculty, delegates, and industry partners for their valuable contributions to the EHA2023 Hybrid Congress.

Read more

FP9 recommendations BioMed Alliance

With preparations under way for the EU’s next Framework Programme for Research and Innovation (FP9), the BioMed Alliance has called for more robust EU support for health research.

Read more

Call for urgent action on medicine shortages in Europe

Medicine shortages are an increasing problem across Europe, posing a severe threat to patient outcomes and patient safety. In a new position paper the European Public Health Alliance (EPHA) presents nine recommendations for addressing the shortages crisis.

Read more

Hematology Tutorials

Hematology Tutorials are courses aiming to provide laboratory and clinical hematologists with an integrated diagnostic and clinical work-up of hematological disorders.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more